Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shatha AbuHammad

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Genomics|December 4, 2012
Gene expression alterations in doxorubicin resistant MCF7 breast cancer cell lineShatha AbuHammad, Malek Zihlif
Nature Chemical Biology|August 11, 2025
Melting KRAS resistanceShatha AbuHammad, Mikolaj Slabicki
Molecular & Cellular Oncology|November 7, 2019
CDK4/6 inhibition in cancer: the cell cycle splicing connectionKaren E Sheppard, Shatha AbuHammad
Case Reports in Dermatology|June 15, 2017
Flare-Up of Rheumatoid Arthritis by Anti-CTLA-4 Antibody but Not by Anti-PD1 Therapy in a Patient with Metastatic MelanomaNicoletta F Jaberg-Bentele, Michael Kunz, Shatha Abuhammad, et al.
Cancers|February 12, 2021
CDK4/6 Inhibition Reprograms Mitochondrial Metabolism in BRAF<sup>V600</sup> Melanoma via a p53 Dependent PathwayNancy T Santiappillai, Shatha Abuhammad, Alison Slater, et al.
Plos One|November 2, 2023
PRMT5 and CDK4/6 inhibition result in distinctive patterns of alternative splicing in melanomaLok Hang Chan, Peihan Wang, Shatha Abuhammad, et al.
Biorxiv : the Preprint Server for Biology|August 1, 2025
Dual Inhibition of CDK4/6 and mTORC1 Establishes a Preclinical Strategy for Translocation Renal Cell CarcinomaShikha Gupta, Prateek Khanna, Eddy Saad, et al.
Scientific Reports|February 6, 2019
A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapyEmily J Lelliott, Carleen Cullinane, Claire A Martin, et al.
International Journal of Cancer|December 16, 2017
Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistanceClaire A Martin, Carleen Cullinane, Laura Kirby, et al.
Cell Reports|February 23, 2022
A genome-scale CRISPR screen reveals PRMT1 as a critical regulator of androgen receptor signaling in prostate cancerStephen Tang, Vidyalakshmi Sethunath, Nebiyou Y Metaferia, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Genomics|December 4, 2012
Gene expression alterations in doxorubicin resistant MCF7 breast cancer cell lineShatha AbuHammad, Malek Zihlif
Nature Chemical Biology|August 11, 2025
Melting KRAS resistanceShatha AbuHammad, Mikolaj Slabicki
Molecular & Cellular Oncology|November 7, 2019
CDK4/6 inhibition in cancer: the cell cycle splicing connectionKaren E Sheppard, Shatha AbuHammad
Case Reports in Dermatology|June 15, 2017
Flare-Up of Rheumatoid Arthritis by Anti-CTLA-4 Antibody but Not by Anti-PD1 Therapy in a Patient with Metastatic MelanomaNicoletta F Jaberg-Bentele, Michael Kunz, Shatha Abuhammad, et al.
Cancers|February 12, 2021
CDK4/6 Inhibition Reprograms Mitochondrial Metabolism in BRAF<sup>V600</sup> Melanoma via a p53 Dependent PathwayNancy T Santiappillai, Shatha Abuhammad, Alison Slater, et al.
Plos One|November 2, 2023
PRMT5 and CDK4/6 inhibition result in distinctive patterns of alternative splicing in melanomaLok Hang Chan, Peihan Wang, Shatha Abuhammad, et al.
Biorxiv : the Preprint Server for Biology|August 1, 2025
Dual Inhibition of CDK4/6 and mTORC1 Establishes a Preclinical Strategy for Translocation Renal Cell CarcinomaShikha Gupta, Prateek Khanna, Eddy Saad, et al.
Scientific Reports|February 6, 2019
A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapyEmily J Lelliott, Carleen Cullinane, Claire A Martin, et al.
International Journal of Cancer|December 16, 2017
Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistanceClaire A Martin, Carleen Cullinane, Laura Kirby, et al.
Cell Reports|February 23, 2022
A genome-scale CRISPR screen reveals PRMT1 as a critical regulator of androgen receptor signaling in prostate cancerStephen Tang, Vidyalakshmi Sethunath, Nebiyou Y Metaferia, et al.
Pageof 2